Literature DB >> 33608534

KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation.

Timothy H Tran1, Albert H Chan1, Lucy C Young2, Lakshman Bindu1, Chris Neale3, Simon Messing1, Srisathiyanarayanan Dharmaiah1, Troy Taylor1, John-Paul Denson1, Dominic Esposito1, Dwight V Nissley1, Andrew G Stephen1, Frank McCormick4,5, Dhirendra K Simanshu6.   

Abstract

The first step of RAF activation involves binding to active RAS, resulting in the recruitment of RAF to the plasma membrane. To understand the molecular details of RAS-RAF interaction, we present crystal structures of wild-type and oncogenic mutants of KRAS complexed with the RAS-binding domain (RBD) and the membrane-interacting cysteine-rich domain (CRD) from the N-terminal regulatory region of RAF1. Our structures reveal that RBD and CRD interact with each other to form one structural entity in which both RBD and CRD interact extensively with KRAS. Mutations at the KRAS-CRD interface result in a significant reduction in RAF1 activation despite only a modest decrease in binding affinity. Combining our structures and published data, we provide a model of RAS-RAF complexation at the membrane, and molecular insights into RAS-RAF interaction during the process of RAS-mediated RAF activation.

Entities:  

Year:  2021        PMID: 33608534     DOI: 10.1038/s41467-021-21422-x

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  47 in total

Review 1.  The RAF proteins take centre stage.

Authors:  Claudia Wellbrock; Maria Karasarides; Richard Marais
Journal:  Nat Rev Mol Cell Biol       Date:  2004-11       Impact factor: 94.444

2.  The RafC1 cysteine-rich domain contains multiple distinct regulatory epitopes which control Ras-dependent Raf activation.

Authors:  M Daub; J Jöckel; T Quack; C K Weber; F Schmitz; U R Rapp; A Wittinghofer; C Block
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

Review 3.  Regulation of RAF protein kinases in ERK signalling.

Authors:  Hugo Lavoie; Marc Therrien
Journal:  Nat Rev Mol Cell Biol       Date:  2015-05       Impact factor: 94.444

Review 4.  Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.

Authors:  Jonathan M L Ostrem; Kevan M Shokat
Journal:  Nat Rev Drug Discov       Date:  2016-07-29       Impact factor: 84.694

5.  Ras interaction with two distinct binding domains in Raf-1 may be required for Ras transformation.

Authors:  J K Drugan; R Khosravi-Far; M A White; C J Der; Y J Sung; Y W Hwang; S L Campbell
Journal:  J Biol Chem       Date:  1996-01-05       Impact factor: 5.157

6.  Mutational analysis of Raf-1 cysteine rich domain: requirement for a cluster of basic aminoacids for interaction with phosphatidylserine.

Authors:  T Improta-Brears; S Ghosh; R M Bell
Journal:  Mol Cell Biochem       Date:  1999-08       Impact factor: 3.396

7.  Cysteine-rich region of Raf-1 interacts with activator domain of post-translationally modified Ha-Ras.

Authors:  C D Hu; K Kariya; M Tamada; K Akasaka; M Shirouzu; S Yokoyama; T Kataoka
Journal:  J Biol Chem       Date:  1995-12-22       Impact factor: 5.157

8.  Two distinct Raf domains mediate interaction with Ras.

Authors:  T R Brtva; J K Drugan; S Ghosh; R S Terrell; S Campbell-Burk; R M Bell; C J Der
Journal:  J Biol Chem       Date:  1995-04-28       Impact factor: 5.157

9.  Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain.

Authors:  Timothy Travers; Cesar A López; Que N Van; Chris Neale; Marco Tonelli; Andrew G Stephen; S Gnanakaran
Journal:  Sci Rep       Date:  2018-05-31       Impact factor: 4.379

10.  Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes.

Authors:  Eunyoung Park; Shaun Rawson; Kunhua Li; Byeong-Won Kim; Scott B Ficarro; Gonzalo Gonzalez-Del Pino; Humayun Sharif; Jarrod A Marto; Hyesung Jeon; Michael J Eck
Journal:  Nature       Date:  2019-10-03       Impact factor: 49.962

View more
  23 in total

1.  Regulation of GTPase function by autophosphorylation.

Authors:  Christian W Johnson; Hyuk-Soo Seo; Elizabeth M Terrell; Moon-Hee Yang; Fenneke KleinJan; Teklab Gebregiworgis; Genevieve M C Gasmi-Seabrook; Ezekiel A Geffken; Jimit Lakhani; Kijun Song; Puspalata Bashyal; Olesja Popow; Joao A Paulo; Andrea Liu; Carla Mattos; Christopher B Marshall; Mitsuhiko Ikura; Deborah K Morrison; Sirano Dhe-Paganon; Kevin M Haigis
Journal:  Mol Cell       Date:  2022-02-23       Impact factor: 17.970

Review 2.  Targeting Mutated KRAS Genes to Treat Solid Tumours.

Authors:  Tharani Krishnan; Rachel Roberts-Thomson; Vy Broadbridge; Timothy Price
Journal:  Mol Diagn Ther       Date:  2021-12-16       Impact factor: 4.074

3.  Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex.

Authors:  Jason J Kwon; Behnoush Hajian; Yuemin Bian; Lucy C Young; Alvaro J Amor; James R Fuller; Cara V Fraley; Abbey M Sykes; Jonathan So; Joshua Pan; Laura Baker; Sun Joo Lee; Douglas B Wheeler; David L Mayhew; Nicole S Persky; Xiaoping Yang; David E Root; Anthony M Barsotti; Andrew W Stamford; Charles K Perry; Alex Burgin; Frank McCormick; Christopher T Lemke; William C Hahn; Andrew J Aguirre
Journal:  Nature       Date:  2022-07-13       Impact factor: 69.504

4.  Functional and biological heterogeneity of KRASQ61 mutations.

Authors:  Minh V Huynh; G Aaron Hobbs; Antje Schaefer; Mariaelena Pierobon; Leiah M Carey; J Nathaniel Diehl; Jonathan M DeLiberty; Ryan D Thurman; Adelaide R Cooke; Craig M Goodwin; Joshua H Cook; Lin Lin; Andrew M Waters; Naim U Rashid; Emanuel F Petricoin; Sharon L Campbell; Kevin M Haigis; Diane M Simeone; Costas A Lyssiotis; Adrienne D Cox; Channing J Der
Journal:  Sci Signal       Date:  2022-08-09       Impact factor: 9.517

5.  Structure of the SHOC2-MRAS-PP1C complex provides insights into RAF activation and Noonan syndrome.

Authors:  Daniel A Bonsor; Patrick Alexander; Kelly Snead; Nicole Hartig; Matthew Drew; Simon Messing; Lorenzo I Finci; Dwight V Nissley; Frank McCormick; Dominic Esposito; Pablo Rodriguez-Viciana; Andrew G Stephen; Dhirendra K Simanshu
Journal:  Nat Struct Mol Biol       Date:  2022-09-29       Impact factor: 18.361

6.  Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.

Authors:  Christian Johnson; Deborah L Burkhart; Kevin M Haigis
Journal:  Cancer Discov       Date:  2022-04-01       Impact factor: 38.272

7.  Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation.

Authors:  Brandon M Murphy; Elizabeth M Terrell; Venkat R Chirasani; Tirzah J Weiss; Rachel E Lew; Andrea M Holderbaum; Aastha Dhakal; Valentina Posada; Marie Fort; Michael S Bodnar; Leiah M Carey; Min Chen; Craig J Burd; Vincenzo Coppola; Deborah K Morrison; Sharon L Campbell; Christin E Burd
Journal:  Nat Commun       Date:  2022-06-07       Impact factor: 17.694

Review 8.  Drug resistance in targeted cancer therapies with RAF inhibitors.

Authors:  Ufuk Degirmenci; Jiajun Yap; Yuen Rong M Sim; Shiru Qin; Jiancheng Hu
Journal:  Cancer Drug Resist       Date:  2021-06-17

9.  A Structure is Worth a Thousand Words: New Insights for RAS and RAF Regulation.

Authors:  Dhirendra K Simanshu; Deborah K Morrison
Journal:  Cancer Discov       Date:  2022-04-01       Impact factor: 39.397

10.  A System for the Evolution of Protein-Protein Interaction Inducers.

Authors:  Jeffrey A Dewey; Saara-Anne Azizi; Vivian Lu; Bryan C Dickinson
Journal:  ACS Synth Biol       Date:  2021-07-28       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.